CD4 and pneumocystosis: Lack of specificity of the COVID‐19 death outcome and other diagnoses such as Pneumocystis jiroveci pneumonia (PJP) in these patients means that some of the association between low CD4 cell count and mortality in patients with COVID‐19 may be from pathology due to PJP rather than COVID‐19 itself.